The COVID-19 pandemic and the use of MS disease-modifying therapies
Uložené v:
| Vydané v: | Multiple sclerosis and related disorders Ročník 39; s. 102073 |
|---|---|
| Hlavní autori: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Netherlands
Elsevier B.V
01.04.2020
|
| Predmet: | |
| ISSN: | 2211-0348, 2211-0356, 2211-0356 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| ArticleNumber | 102073 |
|---|---|
| Author | Hawkes, Chris Levy, Michael Waubant, Emmanuelle Lechner-Scott, Jeannette Gold, Julian Giovannoni, Gavin |
| Author_xml | – sequence: 1 givenname: Gavin surname: Giovannoni fullname: Giovannoni, Gavin email: g.giovannoni@qmul.ac.uk organization: Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK – sequence: 2 givenname: Chris surname: Hawkes fullname: Hawkes, Chris organization: Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK – sequence: 3 givenname: Jeannette surname: Lechner-Scott fullname: Lechner-Scott, Jeannette organization: School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia – sequence: 4 givenname: Michael surname: Levy fullname: Levy, Michael organization: NMO Clinic and Research Laboratory, Division of Neuroimmunology & Neuroinfectious Disease, Massachusetts General Hospital, Boston, USA – sequence: 5 givenname: Emmanuelle surname: Waubant fullname: Waubant, Emmanuelle organization: Department of Neurology, UC San Francisco, San Francisco, California, USA – sequence: 6 givenname: Julian surname: Gold fullname: Gold, Julian organization: Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32334820$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUktr3DAQFiWhSdP8gkLxsRdv9VhpZUoDZfsKpOSQtNdBlmcTbW1pK9mB_feV63RJAmF1GaHvMSN9ekUOfPBIyBtGZ4wy9X4965KJzYxTPp5wuhAvyDHnjJVUSHWw28_1ETlNaU3zUpLNFXtJjgQXGeD0mCyvb7FYXv46_1yyqtgY32DnbJFr0WdkSFiEVfHjqmhcQpOw7ELjVlvnb0Y8mo3D9Jocrkyb8PS-npCfX79cL7-XF5ffzpefLkqrBO9LqZjUTElqrG5qVIpKWjOjqFB6XtVaGm00inltzYIrhrJWNM8rta2lrmkjTsjZ5LsZ6g4bi76PpoVNdJ2JWwjGwWPEu1u4CXewYEIzqbLBu3uDGP4MmHroXLLYtsZjGBJwUUk-ziMz9e3DXrsm_18uE8REsDGkFHG1ozAKY0Swhn8RwRgRTBFlVfVEZV1vehfGgV27R_tx0mJ-4zuHEZJ16C02LqLtoQluj_7sid62zjtr2t-4xbQOQ_Q5PmCQOFC4Gj8QnS6bc6h0NvjwvMHe9n8BumTTIQ |
| CitedBy_id | crossref_primary_10_1007_s40120_022_00349_5 crossref_primary_10_1186_s41983_021_00277_5 crossref_primary_10_3389_fimmu_2020_01459 crossref_primary_10_1186_s12929_022_00847_6 crossref_primary_10_1212_NXI_0000000000001101 crossref_primary_10_3390_ijerph19063366 crossref_primary_10_1002_jmv_26319 crossref_primary_10_12998_wjcc_v8_i17_3669 crossref_primary_10_1016_j_msard_2020_102310 crossref_primary_10_1016_j_ncl_2023_06_006 crossref_primary_10_1007_s10072_022_05901_7 crossref_primary_10_1515_tnsci_2020_0141 crossref_primary_10_3389_fneur_2020_00664 crossref_primary_10_36290_neu_2020_121 crossref_primary_10_1016_j_msard_2022_104172 crossref_primary_10_1016_j_ebiom_2022_104102 crossref_primary_10_1016_j_vaccine_2021_09_030 crossref_primary_10_3390_jcm11092509 crossref_primary_10_1016_j_nrleng_2020_06_001 crossref_primary_10_1016_j_msard_2020_102702 crossref_primary_10_1111_ene_14580 crossref_primary_10_52711_0974_360X_2023_00441 crossref_primary_10_1177_20552173221085242 crossref_primary_10_3389_fimmu_2024_1431403 crossref_primary_10_1016_j_msard_2020_102380 crossref_primary_10_1016_j_msard_2020_102170 crossref_primary_10_1186_s12883_021_02218_4 crossref_primary_10_1007_s10072_020_04570_8 crossref_primary_10_1177_1352458520971817 crossref_primary_10_1177_13524585211005339 crossref_primary_10_3390_vaccines10020279 crossref_primary_10_1111_ncn3_12561 crossref_primary_10_7861_clinmed_2020_0309 crossref_primary_10_1212_NXI_0000000000001001 crossref_primary_10_3390_vaccines9020099 crossref_primary_10_3390_ijms21103544 crossref_primary_10_1016_j_msard_2020_102452 crossref_primary_10_1016_j_msard_2020_102297 crossref_primary_10_1007_s00415_024_12518_7 crossref_primary_10_1016_j_reumae_2020_08_001 crossref_primary_10_1111_cei_13495 crossref_primary_10_1016_j_msard_2023_104840 crossref_primary_10_3389_fnagi_2021_662786 crossref_primary_10_1212_NXI_0000000000000783 crossref_primary_10_1007_s00415_025_13010_6 crossref_primary_10_1016_j_msard_2020_102725 crossref_primary_10_4103_ijpvm_IJPVM_242_20 crossref_primary_10_1002_jmv_26593 crossref_primary_10_1016_j_msard_2020_102204 crossref_primary_10_1016_j_msard_2020_102600 crossref_primary_10_3390_vaccines9070773 crossref_primary_10_1007_s13760_022_02125_6 crossref_primary_10_1016_j_jff_2021_104465 crossref_primary_10_1186_s12883_021_02421_3 crossref_primary_10_33450_fpn_2020_12_004 crossref_primary_10_1016_j_msard_2020_102192 crossref_primary_10_1016_j_msard_2021_103042 crossref_primary_10_1212_NXI_0000000000001141 crossref_primary_10_1016_j_msard_2021_102754 crossref_primary_10_1007_s43440_022_00424_6 crossref_primary_10_1016_j_lfs_2020_118063 crossref_primary_10_1212_NXI_0000000000001024 crossref_primary_10_54101_ACEN_2023_2_7 crossref_primary_10_1016_j_msard_2021_102913 crossref_primary_10_1007_s40120_021_00288_7 crossref_primary_10_1016_j_msard_2020_102516 crossref_primary_10_4103_ijpvm_IJPVM_480_20 crossref_primary_10_1016_j_msard_2021_102908 crossref_primary_10_1177_1352458520949152 crossref_primary_10_3390_cells14080606 crossref_primary_10_1007_s10072_021_05495_6 crossref_primary_10_1016_j_msard_2020_102353 crossref_primary_10_1016_j_jneuroim_2021_577627 crossref_primary_10_1016_j_jns_2020_117230 crossref_primary_10_1002_acn3_51314 crossref_primary_10_1016_j_msard_2021_102886 crossref_primary_10_1016_j_msard_2021_102922 crossref_primary_10_1016_j_msard_2020_102618 crossref_primary_10_12968_bjon_2022_31_7_348 crossref_primary_10_1016_j_msard_2020_102224 crossref_primary_10_33808_clinexphealthsci_943059 crossref_primary_10_1016_j_msard_2020_102185 crossref_primary_10_1016_j_apsb_2021_06_016 crossref_primary_10_1212_NXI_0000000000000753 crossref_primary_10_1007_s10072_021_05373_1 crossref_primary_10_3390_brainsci10060345 crossref_primary_10_1007_s00415_020_09944_8 crossref_primary_10_1177_13524585231218149 crossref_primary_10_1212_NXI_0000000000001046 crossref_primary_10_1016_j_jneuroim_2020_577282 crossref_primary_10_1016_j_msard_2021_102925 crossref_primary_10_1007_s10072_021_05567_7 crossref_primary_10_1007_s40120_020_00225_0 crossref_primary_10_1016_j_msard_2020_102259 crossref_primary_10_1016_j_msard_2021_103180 crossref_primary_10_1212_NXI_0000000000200005 crossref_primary_10_1007_s40263_021_00804_1 crossref_primary_10_1016_j_jneuroim_2021_577690 crossref_primary_10_1007_s00415_020_10112_1 crossref_primary_10_1016_j_lanepe_2024_100979 crossref_primary_10_1016_j_msard_2021_103113 crossref_primary_10_1007_s40263_020_00756_y crossref_primary_10_3389_fphar_2020_621099 crossref_primary_10_5507_bp_2020_033 crossref_primary_10_1007_s00415_020_10045_9 crossref_primary_10_1016_j_msard_2020_102249 crossref_primary_10_1002_jmv_26279 crossref_primary_10_1002_jmv_26796 crossref_primary_10_1016_j_msard_2020_102402 crossref_primary_10_1016_j_msard_2020_102642 crossref_primary_10_1007_s13311_021_01008_7 crossref_primary_10_1155_2021_9982020 crossref_primary_10_1016_j_msard_2020_102482 crossref_primary_10_1007_s12035_021_02464_0 crossref_primary_10_61186_aums_13_4_290 crossref_primary_10_1177_1352458520942198 |
| Cites_doi | 10.1177/1756286419854986 10.1542/peds.113.1.e73 10.1212/WNL.0000000000001302 10.1056/NEJMoa044397 10.1056/NEJMoa020732 10.1371/journal.pmed.1002685 10.1056/NEJMoa1601277 10.1056/NEJMoa1606468 10.1177/1352458510391344 10.1177/1352458513500551 10.2165/00063030-200822020-00002 10.1038/s41591-020-0820-9 10.1056/NEJMoa2002032 10.1016/j.msard.2016.01.005 10.1056/NEJMoa044396 10.1056/NEJMoa2001191 10.1093/cid/cit376 10.1128/JVI.73.4.3338-3350.1999 10.1056/NEJMc1509458 10.1016/S2213-2600(20)30121-1 10.1093/ofid/ofy174 10.1016/S1474-4422(18)30069-3 10.1016/j.msard.2019.01.044 |
| ContentType | Journal Article |
| Copyright | 2020 Elsevier B.V. Elsevier B.V. 2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V. |
| Copyright_xml | – notice: 2020 Elsevier B.V. – notice: Elsevier B.V. – notice: 2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1016/j.msard.2020.102073 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2211-0356 |
| EndPage | 102073 |
| ExternalDocumentID | PMC7138156 32334820 10_1016_j_msard_2020_102073 S2211034820301498 1_s2_0_S2211034820301498 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1P~ 1~. 1~5 4.4 457 4G. 53G 5VS 7-5 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABGSF ABJNI ABMAC ABMZM ABTEW ABUDA ABWVN ABXDB ACDAQ ACGFS ACIEU ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGUBO AGWIK AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKOJK BLXMC BNPGV EBS EFJIC EFKBS EFLBG EJD FDB FEDTE FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM M41 MO0 MOBAO O-L O9- OAUVE OP~ P-8 P-9 PC. Q38 ROL SDF SEL SPCBC SSH SSN SSU SSZ T5K Z5R ~G- ~HD AACTN AFKWA AJOXV AMFUW RIG AADPK AAIAV ABLVK ABYKQ AJBFU DOVZS LCYCR AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c632t-561581650ac8dbe66050b1a6036849b85a8a8e34bca7261e5b6014658cb58b0d3 |
| ISICitedReferencesCount | 94 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000528170700028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2211-0348 2211-0356 |
| IngestDate | Tue Sep 30 15:23:49 EDT 2025 Sat Sep 27 16:23:04 EDT 2025 Wed Feb 19 02:29:54 EST 2025 Wed Nov 05 20:52:13 EST 2025 Tue Nov 18 22:14:29 EST 2025 Fri Feb 23 02:48:23 EST 2024 Sun Feb 23 10:19:58 EST 2025 Tue Oct 14 19:31:09 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Language | English |
| License | Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c632t-561581650ac8dbe66050b1a6036849b85a8a8e34bca7261e5b6014658cb58b0d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7138156 |
| PMID | 32334820 |
| PQID | 2395260365 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7138156 proquest_miscellaneous_2395260365 pubmed_primary_32334820 crossref_primary_10_1016_j_msard_2020_102073 crossref_citationtrail_10_1016_j_msard_2020_102073 elsevier_sciencedirect_doi_10_1016_j_msard_2020_102073 elsevier_clinicalkeyesjournals_1_s2_0_S2211034820301498 elsevier_clinicalkey_doi_10_1016_j_msard_2020_102073 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-04-01 |
| PublicationDateYYYYMMDD | 2020-04-01 |
| PublicationDate_xml | – month: 04 year: 2020 text: 2020-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Multiple sclerosis and related disorders |
| PublicationTitleAlternate | Mult Scler Relat Disord |
| PublicationYear | 2020 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Rudick, Stuart, Calabresi, Confavreux, Galetta, Radue, Lublin, Weinstock-Guttman, Wynn, Lynn, Panzara, Sandrock (bib0021) 2006; 354 Stepanovska, Huwiler (bib0022) 2019 Cook, Vermersch, Comi, Giovannoni, Rammohan, Rieckmann, Sørensen, Hamlett, Miret, Weiner, Viglietta, Musch, Greenberg (bib0003) 2011; 17 Epstein, Dunn, Deresinski (bib0004) 2018; 5 Fragoso, Gama, Gomes, Khouri, Matta, da, Fernanda Mendes, Stella (bib0006) 2016; 6 Woodside, Vanderslice (bib0025) 2008; 22 Ghosh, Goldin, Gordon, Malchow, Rask-Madsen, Rutgeerts, Vyhnálek, Zádorová, Palmer, Donoghue (bib0009) 2003; 348 Yeh, Collins, Cohen, Duffner, Faden (bib0027) 2004; 113 Warny, Helby, Nordestgaard, Birgens, Bojesen (bib0024) 2018; 15 Fragoso, Gama, Gomes, Khouri, Matta, da, Fernanda Mendes, Stella (bib0007) 2016; 6 Luna, Alping, Burman, Fink, Fogdell-Hahn, Gunnarsson, Hillert, Langer-Gould, Lycke, Nilsson, Salzer, Svenningsson, Vrethem, Olsson, Piehl, Frisell (bib0015) 2019 Morfopoulou, Brown, Davies, Anderson, Virasami, Qasim, Chong, Hubank, Plagnol, Desforges, Jacques, Talbot, Breuer (bib0018) 2016; 375 Arbour, Côté, Lachance, Tardieu, Cashman, Talbot (bib0002) 1999; 73 Xinhua (bib0026) 2020 Fine, Sorbello, Kortepeter, Scarazzini (bib0005) 2013; 57 Polman, O'Connor, Havrdova, Hutchinson, Kappos, Miller, Theodore Phillips, Lublin, Giovannoni, Wajgt, Toal, Lynn, Panzara, Sandrock (bib0019) 2006 Kapoor, Ho, Campbell, Chang, Deykin, Forrestal, Lucas, Yu, Arnold, Freedman, Goldman, Hartung, Havrdová, Jeffery, Miller, Sellebjerg, Cadavid, Mikol, Steiner (bib0013) 2018; 17 Andersen, Rambaut, Ian Lipkin, Holmes, Garry (bib0001) 2020 Holshue, DeBolt, Lindquist, Lofy, Wiesman, Bruce, Spitters, Ericson, Wilkerson, Tural, Diaz, Cohn, Fox, Patel, Gerber, Kim, Tong, Lu, Lindstrom, Pallansch, Weldon, Biggs, Uyeki, Pillai (bib0012) 2020; 382 Guan, Ni, Hu, Liang, Ou, He, Liu, Shan, Lei, Hui, Du, Li, Zeng, Yuen, Chen, Tang, Wang, Chen, Xiang, Li, Wang, Liang, Peng, Wei, Liu, Hu, Peng, Wang, Liu, Chen, Li, Zheng, Qiu, Luo, Ye, Zhu, Zhong (bib0010) 2020 Montalban, Hauser, Kappos, Arnold, Bar-Or, Comi, de Seze, Giovannoni, Hartung, Hemmer, Lublin, Rammohan, Selmaj, Traboulsee, Sauter, Masterman, Fontoura, Belachew, Garren, Mairon, Chin, Wolinsky (bib0017) 2017; 376 Francis, Kappos, O'Connor, Collins, Tang, Mercier, Cohen (bib0008) 2014; 20 Kappos, Mehling, Arroyo, Izquierdo, Selmaj, Curovic-Perisic, Keil, Bijarnia, Singh, von Rosenstiel (bib0014) 2015; 84 Hauser, Bar-Or, Comi, Giovannoni, Hartung, Hemmer, Lublin, Montalban, Rammohan, Selmaj, Traboulsee, Wolinsky, Arnold, Klingelschmitt, Masterman, Fontoura, Belachew, Chin, Mairon, Garren, Kappos, OPERA (bib0011) 2017; 376 Stuve, Soelberg Soerensen, Leist, Giovannoni, Hyvert, Damian, Dangond, Boschert (bib0023) 2019; 12 Mayer, Kappos, Racke, Rammohan, Traboulsee, Hauser, Julian, Köndgen, Li, Napieralski, Zheng, Wolinsky (bib0016) 2019; 30 Ramanathan, Antognini, Combes, Paden, Zakhary, Ogino, MacLaren, Brodie, Shekar (bib0020) 2020 Ghosh (10.1016/j.msard.2020.102073_bib0009) 2003; 348 Montalban (10.1016/j.msard.2020.102073_bib0017) 2017; 376 Holshue (10.1016/j.msard.2020.102073_bib0012) 2020; 382 Yeh (10.1016/j.msard.2020.102073_bib0027) 2004; 113 Hauser (10.1016/j.msard.2020.102073_bib0011) 2017; 376 Woodside (10.1016/j.msard.2020.102073_bib0025) 2008; 22 Francis (10.1016/j.msard.2020.102073_bib0008) 2014; 20 Luna (10.1016/j.msard.2020.102073_bib0015) 2019 Mayer (10.1016/j.msard.2020.102073_bib0016) 2019; 30 Fine (10.1016/j.msard.2020.102073_bib0005) 2013; 57 Stuve (10.1016/j.msard.2020.102073_bib0023) 2019; 12 Arbour (10.1016/j.msard.2020.102073_bib0002) 1999; 73 Kapoor (10.1016/j.msard.2020.102073_bib0013) 2018; 17 Kappos (10.1016/j.msard.2020.102073_bib0014) 2015; 84 Polman (10.1016/j.msard.2020.102073_bib0019) 2006 Fragoso (10.1016/j.msard.2020.102073_bib0007) 2016; 6 Warny (10.1016/j.msard.2020.102073_bib0024) 2018; 15 Stepanovska (10.1016/j.msard.2020.102073_bib0022) 2019 Andersen (10.1016/j.msard.2020.102073_bib0001) 2020 Xinhua (10.1016/j.msard.2020.102073_bib0026) 2020 Rudick (10.1016/j.msard.2020.102073_bib0021) 2006; 354 Epstein (10.1016/j.msard.2020.102073_bib0004) 2018; 5 Guan (10.1016/j.msard.2020.102073_bib0010) 2020 Cook (10.1016/j.msard.2020.102073_bib0003) 2011; 17 Morfopoulou (10.1016/j.msard.2020.102073_bib0018) 2016; 375 Ramanathan (10.1016/j.msard.2020.102073_bib0020) 2020 Fragoso (10.1016/j.msard.2020.102073_bib0006) 2016; 6 32403068 - Mult Scler Relat Disord. 2020 Jul;42:102170 |
| References_xml | – volume: 12 year: 2019 ident: bib0023 article-title: Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers publication-title: Ther. Adv. Neurol. Disord. – volume: 15 year: 2018 ident: bib0024 article-title: Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study publication-title: PLoS Med. – volume: 57 start-page: 849 year: 2013 end-page: 852 ident: bib0005 article-title: Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients publication-title: Clin. Infect. Dis. – year: 2020 ident: bib0010 article-title: Clinical characteristics of coronavirus disease 2019 in China publication-title: N. Engl. J. Med. – volume: 354 start-page: 911 year: 2006 end-page: 923 ident: bib0021 article-title: Natalizumab plus interferon beta-1a for relapsing multiple sclerosis publication-title: N. Engl. J. Med. – volume: 30 start-page: 236 year: 2019 end-page: 243 ident: bib0016 article-title: Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies publication-title: Mult. Scler. Relat. Disord. – volume: 73 start-page: 3338 year: 1999 end-page: 3350 ident: bib0002 article-title: Acute and persistent infection of human neural cell lines by human coronavirus OC43 publication-title: J. Virol. – volume: 6 start-page: 64 year: 2016 end-page: 65 ident: bib0007 article-title: Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab publication-title: Mult. Scler. Relat. Disord. – year: 2019 ident: bib0015 article-title: Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies publication-title: JAMA Neurol. – volume: 376 start-page: 209 year: 2017 end-page: 220 ident: bib0017 article-title: Ocrelizumab versus Placebo in primary progressive multiple sclerosis publication-title: N. Engl. J. Med. – volume: 113 start-page: e73 year: 2004 end-page: e76 ident: bib0027 article-title: Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis publication-title: Pediatrics – year: 2020 ident: bib0026 article-title: Beijing hospital confirms nervous system infections by novel coronavirus [WWW Document] publication-title: XinhuaNet – volume: 6 start-page: 64 year: 2016 end-page: 65 ident: bib0006 article-title: Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab publication-title: Mult. Scler. Relat. Disord. – volume: 17 start-page: 405 year: 2018 end-page: 415 ident: bib0013 article-title: Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension publication-title: Lancet Neurol. – volume: 348 start-page: 24 year: 2003 end-page: 32 ident: bib0009 article-title: Natalizumab for active Crohn's disease publication-title: N. Engl. J. Med. – volume: 5 start-page: ofy174 year: 2018 ident: bib0004 article-title: Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management publication-title: Open Forum Infect. Dis. – volume: 20 start-page: 471 year: 2014 end-page: 480 ident: bib0008 article-title: Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy publication-title: Mult. Scler. – volume: 382 start-page: 929 year: 2020 end-page: 936 ident: bib0012 article-title: First case of 2019 novel coronavirus in the United States publication-title: N. Engl. J. Med. – volume: 84 start-page: 872 year: 2015 end-page: 879 ident: bib0014 article-title: Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis publication-title: Neurology – year: 2019 ident: bib0022 article-title: Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases publication-title: Pharmacol. Res. – volume: 22 start-page: 85 year: 2008 end-page: 100 ident: bib0025 article-title: Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive pulmonary disease publication-title: BioDrugs – year: 2020 ident: bib0001 article-title: The proximal origin of SARS-CoV-2 publication-title: Nat. Med. – volume: 376 start-page: 221 year: 2017 end-page: 234 ident: bib0011 article-title: Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis publication-title: N. Engl. J. Med. – volume: 17 start-page: 578 year: 2011 end-page: 593 ident: bib0003 article-title: Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study publication-title: Mult. Scler. – volume: 375 start-page: 497 year: 2016 end-page: 498 ident: bib0018 article-title: Human coronavirus OC43 associated with fatal encephalitis publication-title: N. Engl. J. Med. – year: 2006 ident: bib0019 article-title: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis publication-title: N. Engl. J. Med. – year: 2020 ident: bib0020 article-title: Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases publication-title: Lancet Respir. Med. – volume: 12 year: 2019 ident: 10.1016/j.msard.2020.102073_bib0023 article-title: Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers publication-title: Ther. Adv. Neurol. Disord. doi: 10.1177/1756286419854986 – volume: 113 start-page: e73 year: 2004 ident: 10.1016/j.msard.2020.102073_bib0027 article-title: Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis publication-title: Pediatrics doi: 10.1542/peds.113.1.e73 – volume: 84 start-page: 872 year: 2015 ident: 10.1016/j.msard.2020.102073_bib0014 article-title: Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis publication-title: Neurology doi: 10.1212/WNL.0000000000001302 – year: 2006 ident: 10.1016/j.msard.2020.102073_bib0019 article-title: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa044397 – volume: 348 start-page: 24 year: 2003 ident: 10.1016/j.msard.2020.102073_bib0009 article-title: Natalizumab for active Crohn's disease publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa020732 – volume: 15 year: 2018 ident: 10.1016/j.msard.2020.102073_bib0024 article-title: Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study publication-title: PLoS Med. doi: 10.1371/journal.pmed.1002685 – volume: 376 start-page: 221 year: 2017 ident: 10.1016/j.msard.2020.102073_bib0011 article-title: Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1601277 – volume: 376 start-page: 209 year: 2017 ident: 10.1016/j.msard.2020.102073_bib0017 article-title: Ocrelizumab versus Placebo in primary progressive multiple sclerosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1606468 – volume: 17 start-page: 578 year: 2011 ident: 10.1016/j.msard.2020.102073_bib0003 article-title: Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study publication-title: Mult. Scler. doi: 10.1177/1352458510391344 – volume: 20 start-page: 471 year: 2014 ident: 10.1016/j.msard.2020.102073_bib0008 article-title: Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy publication-title: Mult. Scler. doi: 10.1177/1352458513500551 – volume: 22 start-page: 85 year: 2008 ident: 10.1016/j.msard.2020.102073_bib0025 article-title: Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive pulmonary disease publication-title: BioDrugs doi: 10.2165/00063030-200822020-00002 – year: 2020 ident: 10.1016/j.msard.2020.102073_bib0001 article-title: The proximal origin of SARS-CoV-2 publication-title: Nat. Med. doi: 10.1038/s41591-020-0820-9 – year: 2020 ident: 10.1016/j.msard.2020.102073_bib0010 article-title: Clinical characteristics of coronavirus disease 2019 in China publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2002032 – volume: 6 start-page: 64 year: 2016 ident: 10.1016/j.msard.2020.102073_bib0007 article-title: Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab publication-title: Mult. Scler. Relat. Disord. doi: 10.1016/j.msard.2016.01.005 – volume: 354 start-page: 911 year: 2006 ident: 10.1016/j.msard.2020.102073_bib0021 article-title: Natalizumab plus interferon beta-1a for relapsing multiple sclerosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa044396 – volume: 382 start-page: 929 year: 2020 ident: 10.1016/j.msard.2020.102073_bib0012 article-title: First case of 2019 novel coronavirus in the United States publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2001191 – volume: 57 start-page: 849 year: 2013 ident: 10.1016/j.msard.2020.102073_bib0005 article-title: Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients publication-title: Clin. Infect. Dis. doi: 10.1093/cid/cit376 – volume: 73 start-page: 3338 year: 1999 ident: 10.1016/j.msard.2020.102073_bib0002 article-title: Acute and persistent infection of human neural cell lines by human coronavirus OC43 publication-title: J. Virol. doi: 10.1128/JVI.73.4.3338-3350.1999 – volume: 6 start-page: 64 year: 2016 ident: 10.1016/j.msard.2020.102073_bib0006 article-title: Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab publication-title: Mult. Scler. Relat. Disord. doi: 10.1016/j.msard.2016.01.005 – volume: 375 start-page: 497 year: 2016 ident: 10.1016/j.msard.2020.102073_bib0018 article-title: Human coronavirus OC43 associated with fatal encephalitis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc1509458 – year: 2020 ident: 10.1016/j.msard.2020.102073_bib0020 article-title: Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(20)30121-1 – volume: 5 start-page: ofy174 year: 2018 ident: 10.1016/j.msard.2020.102073_bib0004 article-title: Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management publication-title: Open Forum Infect. Dis. doi: 10.1093/ofid/ofy174 – year: 2019 ident: 10.1016/j.msard.2020.102073_bib0015 article-title: Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies publication-title: JAMA Neurol. – year: 2020 ident: 10.1016/j.msard.2020.102073_bib0026 article-title: Beijing hospital confirms nervous system infections by novel coronavirus [WWW Document] publication-title: XinhuaNet – volume: 17 start-page: 405 year: 2018 ident: 10.1016/j.msard.2020.102073_bib0013 article-title: Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(18)30069-3 – volume: 30 start-page: 236 year: 2019 ident: 10.1016/j.msard.2020.102073_bib0016 article-title: Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies publication-title: Mult. Scler. Relat. Disord. doi: 10.1016/j.msard.2019.01.044 – year: 2019 ident: 10.1016/j.msard.2020.102073_bib0022 article-title: Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases publication-title: Pharmacol. Res. – reference: 32403068 - Mult Scler Relat Disord. 2020 Jul;42:102170 |
| SSID | ssj0000651461 |
| Score | 2.5412257 |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 102073 |
| SubjectTerms | Betacoronavirus - isolation & purification Coronavirus Infections - epidemiology Coronavirus Infections - immunology Coronavirus Infections - prevention & control COVID-19 Humans Multiple Sclerosis - drug therapy Multiple Sclerosis - epidemiology Multiple Sclerosis - immunology Multiple Sclerosis - virology Neurology Pandemics - prevention & control Pneumonia, Viral - epidemiology Pneumonia, Viral - immunology Pneumonia, Viral - prevention & control SARS-CoV-2 |
| Title | The COVID-19 pandemic and the use of MS disease-modifying therapies |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2211034820301498 https://www.clinicalkey.es/playcontent/1-s2.0-S2211034820301498 https://dx.doi.org/10.1016/j.msard.2020.102073 https://www.ncbi.nlm.nih.gov/pubmed/32334820 https://www.proquest.com/docview/2395260365 https://pubmed.ncbi.nlm.nih.gov/PMC7138156 |
| Volume | 39 |
| WOSCitedRecordID | wos000528170700028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 2211-0356 dateEnd: 20210531 omitProxy: false ssIdentifier: ssj0000651461 issn: 2211-0348 databaseCode: AIEXJ dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfYhqa9IL4pH5OReBupHOfLfpzKGJu0gdSB-mbZiSMyaFot7difzzm2k46yAQ-8tFViO43v58v5cvc7hN6QvEyJLmmgOSuCmJE44JrqgMhQRYzkoSpZW2wiOz1lkwn_5Hy6TVtOIKtrdnXF5_9V1HAMhG1SZ_9B3N2gcAB-g9DhE8QOn38t-NHHL0fvgpDvzY2PeOo4WY2NubS-e9i-u1czwXRWVDbZyeZi-ahCX-bJRxw2cB14pFaW1LnNgQFjtXDsnZ1pfmiiW-t61paK2juUl1Xda7kf33RPadDHAuUm7SYY5y545FhLkyy00H0LW1h5NcbfeSooWQlw0a1Go9T4YyPLJO7Vr-UycvoTzB1iS5usqXbrZTgfThtYOkMz_nC9NYhiPm0FG1GTY0xJ_5zrog_9qQ20RbOEgy7c2j86mBx3vjkwy0y5c09S1YYDrl12B237gW6yadb3LL-G3q7YMmf30T23CcH7FjwP0B1dP0TbJy7M4hEaAYawxxD2GMLwjQEjGDCEZyU-GeM1DOEOQ4_R5_cHZ6MPgau2EeRpRBcBGNIJC8FglzkrlE5hn0tUKFMwcVjMFUskk0xHscplBttunajUEA8lLFcJU6SInqBNAJd-hnCoYN_GmKRElnEWa0aLmNCy4DHMG1NsgKifL5E7KnpTEeW78DGH56Kdb2HmW9j5HqC3Xae5ZWK5vXnsBSF8kjE8FgXA6fZu2e-66cat8EaEoqGCiLEBM2nFb7wSHG4q7Xo669VapX--5GuPEwG63bywk7WeLRtBI55QI4BkgJ5a3HS37rEHf_gaoroGhjf--pm6-tryx2dhZDiint845gu006_fl2hzcbHUr9Dd_HJRNRe7aCObsF23Zn4C2gXaDw |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+COVID-19+pandemic+and+the+use+of+MS+disease-modifying+therapies&rft.jtitle=Multiple+sclerosis+and+related+disorders&rft.au=Giovannoni%2C+Gavin&rft.au=Hawkes%2C+Chris&rft.au=Lechner-Scott%2C+Jeannette&rft.au=Levy%2C+Michael&rft.date=2020-04-01&rft.eissn=2211-0356&rft.volume=39&rft.spage=102073&rft_id=info:doi/10.1016%2Fj.msard.2020.102073&rft_id=info%3Apmid%2F32334820&rft.externalDocID=32334820 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F22110348%2FS2211034819X00127%2Fcov150h.gif |